We are a Swiss law firm, dedicated to providing legal solutions to business, tax and regulatory matters.
Dedicated to our clients' success
Services
Intellectual Property
Life Sciences, Pharma, Biotech
Litigation and Arbitration
Meet our team
Our knowledge, expertise & publications
View all
Events
Deals & Cases
Careers
25 October 2016
CRISPR Therapeutics AG (NASDAQ:CRSP), a biopharmaceutical company focused on translating CRISPR/Cas9 gene-editing technology into transformative medicines, announced on October 18, 2016 the pricing of its initial public offering of 4'000'000 common shares at a public offering price of $14.00 per share. CRISPR Therapeutics’ common shares have started trading on the NASDAQ Global Market under the ticker symbol "CRSP" on October 19, 2016. Citigroup, Piper Jaffray and Barclays acted as joint book-running managers for the offering. Guggenheim Securities acted as co-manager. In addition to the shares sold in the public offering, CRISPR Therapeutics also completed the concurrent sale of an additional 2'500'000 shares at the initial offering price of $14.00, for gross proceeds of $35.0 million, in a private placement to Bayer Global Investments B.V., an existing shareholder and an affiliate of Bayer HealthCare LLC, a joint venture partner with CRISPR Therapeutics. VISCHER AG and Goodwin Procter LLP are legal advisors to the Company.
The team at VISCHER is led by Matthias Staehelin (Partner Corporate) with Stefan Grieder (Partner Corporate), Nadia Tarolli (Partner Tax), Angelo Imperiale, Gian Caprez, Vincent Reardon and Luzius Zumstein (all Associates).
Categories: Corporate and commercial, Life Sciences, Pharma, Biotech, Private Equity & Venture Capital, Startup Desk, Deals & Cases
Attorney at Law and Civil Law Notary (BS/BL)
Attorney at Law
Attorney at Law, Swiss Certified Tax Expert (2008)
Swiss dental startup Odne (former Lumendo) has raised USD 5.5m to fund the upcoming US market launch...
Artiria Medical SA, a Swiss neurovascular MedTech company developing next-generation...
GlycoEra AG in Wädenswil, has increased its Series A Financing Round with a substantial additional...